Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023
October 31, 2023 10:38 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) Presented Data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 24, 2023 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., May 24, 2023 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) Presented Updated Data at the American Association for Cancer Research (AACR) Annual Meeting
May 02, 2023 10:12 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer
August 18, 2022 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., May 26, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 17, 2022 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen...
Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
April 21, 2022 08:00 ET
|
Innovative Cellular Therapeutics
Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose of...
Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer
April 19, 2022 08:00 ET
|
Innovative Cellular Therapeutics
GCC19CART is an autologous CAR T therapy candidate that has shown promising results in over 30 R/R mCRC patients in ChinaICT plans to initiate a Phase 1 Trial of GCC19CART in the U.S. for the...
斯丹賽生物技術公司任命 Lucy Lu 博士為首席運營官
April 06, 2022 20:00 ET
|
Innovative Cellular Therapeutics
馬里蘭州羅克維爾, April 07, 2022 (GLOBE NEWSWIRE) -- 致力於開發以實體瘤為重點的嵌合抗原受體（CAR）T細胞治療綜合平台的臨床階段生物技術公司--斯丹賽生物技術（即：Innovative Cellular Therapeutics，簡稱“ICT”）今天宣佈，任命Lucy Lu 醫學博士為首席運營官。 ...
斯丹赛生物技术公司任命Robert Dallimore 作为质量与合规高级副总裁
April 06, 2022 20:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., April 07, 2022 (GLOBE NEWSWIRE) -- 致力于开发以实体瘤为重点的嵌合抗原受体（CAR）T细胞治疗综合平台的临床阶段生物技术公司--斯丹赛生物技术（即：Innovative Cellular Therapeutics，简称“ICT”）今天宣布，任命 Robert Dallimore 为质量与合规高级副总裁。 ...